<DOC>
	<DOCNO>NCT01903902</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety paclitaxel-eluting balloon ( SeQuent® Please ) treatment lesion native small coronary artery .</brief_summary>
	<brief_title>Efficacy Safety Paclitaxel-eluting Balloon Treatment Lesions Native Small Coronary Arteries</brief_title>
	<detailed_description>Drug-eluting balloon ( DEB ) emerge potential alternative overcome limitation drug-eluting stent restenosis stent thrombosis . DEB angioplasty proven effective clinically treatment in-stent restenosis . However , DEB de novo lesion , especially small vessel less study . The purpose study evaluate efficacy safety paclitaxel-eluting balloon ( SeQuent® Please ) treatment lesion native small coronary artery .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Age ≥ 19 year Patients appropriate percutaneous coronary intervention use drugeluting balloon native small coronary artery ( vessel diameter ≥ 2.25 mm ≤ 2.75 mm , lesion length &lt; 25 mm ) Informed consent Chronic total obstruction lesion Severe calcify lesion Left main coronary lesion Lesion intravascular thrombus Shock status cause include cardiogenic shock Left ventricular ejection fraction &lt; 30 % Need coronary artery bypass surgery Allergic reaction paclitaxel Severe allergic contrast agent ( Visipaque ) statin Pregnancy , breastfeed Expectation pregnancy woman childbearing age</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Coronary artery disease</keyword>
	<keyword>Balloon angioplasty</keyword>
	<keyword>Drug-eluting balloon</keyword>
</DOC>